Nordic Life Science 1
xxx xxx CEO of QureTech Bio xxx xxx HELÉN FÄLT ha
s been appointed new acting CEO, replacing Fredrik Almqvist, one of the company’s original founders. Fält has previously worked as QureTech Bio’s business coach at Umeå Biotech Incubator (UBI). She has worked within life science research and development as well as pharmaceutical contract manufacturing, and has also participated in clinical studies in the Västerbotten region. “I have worked in this industry XXX xxx xxx throughout my entire professional life in various organizations and positions. I have a background in research, which means that I know what is needed for the company to succeed, but also that I understand the conditions that founders, owners and employees have. At UBI I have worked with all phases in the development of startups. In recent years I have worked intensely with financing and growth, participated as an adjunct board member in several startups and established a wide network of contacts,” says Fält. 16 NORDICLIFESCIENCE.ORG CEO of the Center for Translational Research Sweden xxx xxx KARIN MEYER succeeds Mats Lindquist, who has been CEO since the foundation of CTR in 2016. Her new position will start on May 1st 2021. Meyer has long experience of having management roles within the pharma and biotech industry. She has a great knowledge of this branch of industry and a very good understanding of the development of new products within these areas. She is a pharmacist and most recently she was CEO of the Swedish Pharmaceutical Society. “I really look forward to this assignment and, together with the board and the companies in the CTR sphere, continuing to expand the organization. To build a strong and well coherent structure in order to make competence available to national and international customers within the pharma and medtech areas is extremely important for life sciences in Sweden, and it is also something that I personally am passionate about,” says Meyer. CEO of the Novo Nordisk Foundation xxx xxx Head of Research at Lundbeck MADS KROGSGAARD THOMSEN succeeds Birgitte Nauntofte, who has been appointed as board member of both LIFE and the BioInnovation Institute. “For many years, I have been following the incredible development of the Novo Nordisk Foundation at close range, and it is both with a sense of enthusiasm and humility that I now take over the reins after Birgitte,” says Krogsgaard Thomsen. “Today, the Novo Nordisk Foundation is one of the three biggest foundations in the world. Over the past couple of years it has built a highly experienced and competent organization, which I look forward to working with. The ambition is to support even more initiatives and projects that benefit people and society.” Krogsgaard Thomsen, who has been CSO at Novo Nordisk since 2000 and started at the company in 1991, also announced that he is retiring from Novo Nordisk. TAREK SAMAD will join the company on 1 May 2021 as Senior Vice President, Head of Research. He brings experience in drug development from academia and industry, including Louis Pasteur University, Harvard Medical School, Pfizer, and Sanofi. He has led discovery of small molecules and biopharmaceuticals in neuroscience and inflammation for both diseasemodifying and symptomatic approaches. His research has been focused on studying changes of the nervous system and their implications across a wide range of neurological disorders. He joins Lundbeck from Immunitas Therapeutics, US, where he was most recently CSO. “Lundbeck has a great history of discovering innovative drug candidates and bringing them to serve patients who live with brain diseases. I am thrilled to be able to build on Lundbeck’s strong heritage in neuroscience,” says Samad. PHOTO OLA JACOBSEN PHOTO JANTZEN